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Summary
Recent actions by the Department of Health and Human Services (HHS) and the
National Institutes of Health (NIH) involving human embryonic stem cell research have
rekindled debate over the difficult ethical and social issues surrounding embryo and fetal
tissue research.  Embryonic stem cells, which have the ability to develop into virtually
any cell in the body, may have the potential to treat medical conditions such as diabetes,
Parkinson’s disease, and cancer.  Following an HHS determination that the current ban
on federal funding of human embryo research does not prohibit funding human
embryonic stem cell research, NIH published guidelines for the support of such research
in the Federal Register on August 25, 2000.  The Stem Cell Research Act of 2000, S.
2015 (Specter), would allow federal support of research on the creation and use of
human embryonic stem cells.  However, other Members strongly disagree with the HHS
decision and believe such research is banned by the rider that has been attached to each
Labor, Health and Human Services and Education appropriations bill since 1995.  This
report, which will be updated as needed, discusses the status of research and key issues
associated with human embryonic stem cells.
Embryonic Stem Cell Research and Potential Applications
Although most cells within an animal or human being are committed to fulfilling a
single function in an organ like the skin or heart, a unique and important set of cells exists
which is not so specialized.  These stem cells – cells which retain the ability to become
many or all of the different cell types in the body – play a critical role in repairing organs
and body tissues throughout life.  Although the term “stem cells” usually refers to these
repair cells within an adult organism, a more fundamental variety of stem cells is found in
the early stage embryo.  These embryonic stem cells have a greater ability to become
different types of body cells than adult stem cells.  The earliest embryonic stem cells are
referred to as totipotent, indicating that they can develop into an entire organism because
they can produce both the embryo and the tissues required to support it in the uterus.
Later in development, embryonic stem cells lose the ability to form these supporting
tissues, but are still able to develop into almost any cell type found in the body.  These
pluripotent embryonic stem cells are the current focus of intense research interest.
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1 In contrast, HHS regulations define fetus as “the product of conception from the time of
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Embryonic stem cells were first isolated from mice in 1981 and until recently,
scientists have used only animal embryonic stem cells in research.  In November 1998, two
groups published the results of their work on human stem cells from embryos or fetuses.
For human development, the term embryo is used for the first 8 weeks after fertilization,
and fetus for the 9th week through birth.1  In both cases, the embryos and fetuses were
donated for research purposes following a process of informed consent.  University of
Wisconsin researchers derived stem cells from 1 week old embryos produced via in vitro
fertilization (IVF) for the treatment of infertility.  Because the stem cells are located within
the embryo, the process of removing the cells destroys the embryo.  Johns Hopkins
University investigators derived cells with very similar properties from 5 to 9 week old
embryos or fetuses obtained through elective abortions.
Another potential source of embryonic stem cells is somatic2 cell nuclear transfer, the
cloning procedure used to produce Dolly, the sheep.  Geron Corporation, a Menlo Park,
California biotechnology company is currently funding work on stem cells created via this
process.3  An alternate approach is the fusion of adult human cells with egg cells of other
animals.  In 1996, researchers at the University of Massachusetts fused a human cheek cell
with a cow egg cell.  The resulting hybrid cell had “embryo-like” characteristics and was
generated for the purpose of making stem cells.  This method is currently being pursued
by Advanced Cell Technology Co. of Worcester, MA.4  Stem cells obtained from adult
organisms are also the focus of research.  However, some scientists believe adult stem cells
should not be considered as an alternative to embryonic stem cells because of important
scientific and technical limitations.5 
Stem cell research was chosen by Science magazine in 1999 as its “breakthrough of
the year.”  Stem cells provide the opportunity to study the growth and differentiation of
individual cells.  Understanding these processes could provide insights into the causes of
birth defects, genetic abnormalities, and other disease states.  If normal development were
better understood, it might be possible to prevent or correct some of these conditions.
Stem cells could be used to produce large amounts of one cell type to test new drugs for
effectiveness and chemicals for toxicity.  Stem cells might be transplanted into the body
to treat disease or injury (e.g., spinal cord).  The damaging side effects of medical
treatments might be repaired with stem cell treatment.  For example, cancer chemotherapy
destroys immune cells in patients making it difficult to fight off a broad range of diseases;
correcting this adverse effect would be a major advance.  Before stem cells can be applied
to human medical problems, substantial advances in basic cell biology and clinical
technique are required.  The potential benefits mentioned  previously are likely only after
many more years of research.  Technical hurdles include developing the ability to control
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106-113, prohibits HHS from using FY2000 appropriated funds for “(1) the creation of a human
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the differentiation of stem cells into a desired cell type (like a heart or nerve cell),  and, if
stem cells are to be used for transplantation, the problem of immune rejection must also
be overcome.
Federal Funding of Research
To date, no federal funds have been used to support research on stem cells derived
from either human embryos or fetal tissue obtained from abortions.  The work at the
University of Wisconsin and Johns Hopkins University was supported by private funding
from Geron Corporation.  Private funding for experiments involving embryos was required
because Congress has attached a rider to the Labor, Health and Human Services and
Education appropriations bill each year since FY1996 which prohibits HHS from using
appropriated funds for the creation of human embryos for research purposes or for
research in which human embryos are destroyed.  This prohibition has been attached to
subsequent appropriations bills through the current fiscal year.6  There is no similar federal
prohibition on fetal tissue research; however, other restrictions do apply (see below).
Following the November 1998 announcement on the derivation of human embryonic
stem cells, NIH requested a legal opinion from HHS on whether federal funds could be
used to support research on human stem cells derived from embryos or fetal tissue.  The
January 15, 1999, response from HHS General Counsel Harriet Rabb found that current
law prohibiting the use of HHS appropriations for human embryo research (the above
mentioned rider) would not apply to research using human stem cells “because such cells
are not a human embryo within the statutory definition.”  The finding was based, in part,
on HHS’s determination that the statutory ban on human embryo research defines an
embryo as an organism.  Human pluripotent stem cells are not and cannot develop into an
organism; they lack the capacity to become organisms even if they are transferred to a
uterus.  As a result, HHS maintained that NIH could support research which uses stem
cells but could not support research which derives stem cells from embryos.
Regarding research using stem cells derived from fetal tissue, HHS found that to the
extent human stem cells are legally considered fetal tissue, they would be subject to certain
other restrictions which safeguard against the inappropriate use of fetuses.  For example,
the statutory ban on sale for valuable consideration  prohibits researchers with federal
support from paying for the tissue, except reasonable payments associated with
transportation, implantation, processing, preservation, quality control or storage of the
tissue or cells.  Other restrictions include the criminal prohibition on the directed donation
of fetal tissue and the restrictions on fetal tissue transplantation research conducted or
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10 The British report “Stem Cell Research: Medical Progress With Responsibility,” was released
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funded by HHS.7  In addition, such research may be conducted only in accordance with
applicable state or local law.8
Shortly after the opinion by the HHS General Counsel, NIH disclosed that the agency
planned to fund research on pluripotent stem cells derived from human embryos and fetal
tissue once appropriate guidelines were developed and an oversight committee established.
NIH Director Harold Varmus appointed a working group which began drafting guidelines
in April 1999.  Draft guidelines were published in the Federal Register on December 2,
1999.  About 50,000 comments were received during the public comment period which
ended February 22, 2000.  On August 23 NIH released final guidelines on the support of
human embryonic and fetal stem cell research; Federal Register publication occurred on
August 25, 2000.  NIH will begin accepting grant applications for research projects
utilizing human stem cells immediately.  All such applications will be reviewed by the new
NIH Human Pluripotent Stem Cell Review Group which was established to ensure
compliance with the guidelines.   Applications will also undergo the normal NIH peer-
review process.  The first grants are expected to be awarded in mid 2001. 
The NIH guidelines prohibit funding for the derivation of human stem cells from
embryos remaining after infertility treatment; this is currently prohibited by the previously
mentioned appropriation rider.  In this respect, the NIH is more restrictive than other
groups such as the National Bioethics Advisory Commission (NBAC)9 and an expert
British panel10 which both recommended support for the derivation of stem cells from such
embryos.  The NIH guidelines allow funding of research to derive stem cells from fetal
tissue, as well as research utilizing such stem cells; this is in agreement with NBAC
recommendations and current law.  Other areas of research ineligible for NIH funding
under the guidelines include: (1) research in which human stem cells are utilized to create
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or contribute to a human embryo; (2) research in which human stem cells are combined
with an animal embryo; (3) research in which human stem cells are used for reproductive
cloning of a human; (4) research in which human stem cells are derived using somatic cell
nuclear transfer, i.e., the transfer of a human somatic cell nucleus into a human or animal
egg; (5) research utilizing human stem cells that were derived using somatic cell nuclear
transfer; and (6) research utilizing stem cells that were derived from human embryos
created for research purposes, rather than for infertility treatment.  The NBAC report is
silent on areas 1-3 and in agreement with the guidelines on areas 4-6. 
Congressional Actions
The January 15, 1999 opinion by HHS General Counsel Harriet Rabb and the
decision by NIH to fund human embryonic stem cell research in the near future was
strongly opposed by many Members of Congress.  In a February 11, 1999 letter from 70
Members to HHS Secretary Donna Shalala, they stated that “any NIH action to initiate
funding of such research would violate both the letter and the spirit of the federal law
banning federal support for research in which human embryos are harmed or destroyed.”
The authors of the letter also object to HHS General Counsel Rabb’s definition of human
embryo, which is that “an entity is an embryo only if one can show that it is capable, if
implanted in the womb, of becoming a born human being.”  The letter states that “this
narrow definition has no support whatsoever in federal law.”  In a February 23, 1999
letter, Secretary of HHS Donna Shalala responded that the definition of embryo used in
the HHS opinion “relies on the definition provided in the statute itself.”  Secretary
Shalala’s letter states that the federal ban only applies to research in which human embryos
are discarded or destroyed but “not to research preceding or following on such projects
[in which human embryos are discarded or destroyed].  Moreover, ... there is nothing in
the legislative history to suggest that the provision was intended to prohibit funding for
research in which embryos – organisms – are not involved.”
The stem cell research issue threatened to hold up passage of the FY2000 Labor,
Health and Human Services and Education appropriations bill.  In the House,
Representative Jay Dickey proposed an amendment to restrict federally funded stem cell
research to work on cells derived from fetal tissue.  Representative  Dickey, the author of
the congressional funding ban on embryo research, withdrew his amendment at the request
of House leadership who were concerned that controversial amendments might slow down
passage of the appropriation bill.  In the Senate, the issue held up passage of the FY2000
LHHS appropriation bill until Senate leadership agreed to drop language endorsing the
research and take it up as a separate bill in the second session.
S. 2015 (Specter), introduced on January 31, 2000, would give NIH authority to fund
the derivation of stem cells from surplus IVF embryos, an activity forbidden under the NIH
guidelines and prohibited by the appropriation bill rider.  In contrast, the bill broadly
prohibits support of embryo research unrelated to stem cells.  This provision represents
a more permanent legislative prohibition than the appropriations rider (which must be
renewed each year) banning support of research involving the destruction of human
embryos.  On February 2, 2000, H.Res. 414 (Maloney) was introduced in the House
“expressing the sense of the House of Representatives supporting federal funding directed
toward human pluripotent stem cell research to further research into Parkinson’s disease
and other medical conditions.”  On February 4, 2000, a group of 20 Republican Senators
reportedly sent a letter to DHHS in opposition to the proposed NIH guidelines for support
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of human embryonic stem cell research asserting that such support is contrary to the
requirements of the agency’s appropriations language.  The authors of the letter ask that
NIH withdraw the proposed guidelines, and indicate that should the NIH adopt the draft
guidelines, further steps might be taken to oppose them, including a possible lawsuit to
enforce the federal ban.11
Ethical Issues
The central controversy surrounding human stem cell research is the source of the
cells.  The debate primarily arises from differences in deeply held religious and philosophic
views.  For most who believe that the embryo is a human being from the moment of
fertilization, the derivation of stem cells from either very early or pre-implantation embryos
created by IVF or from the tissues of aborted fetuses is ethically unacceptable.   From this
viewpoint, even though the proposed guidelines do not support activities which directly
destroy embryos, support of research on components of the embryo would tacitly endorse
such destruction.  Supporters of this view argue therefore that the guidelines would violate
federal bans on human embryo research.   From this perspective, the possible benefits of
stem cell research cannot and should not justify the actions necessary to obtain the cells.
Opponents of stem cell research propose that research on adult stem cells, which they
claim could provide similar therapeutic benefits without the need for fetal cells, be
supported instead.  Not all scientists agree, however, that adult stem cells hold as much
potential as embryonic stem cells. 
Those who support embryonic stem cell research believe that pre-implantation
embryos do not have the same moral and legal status as persons.  They acknowledge that
embryos are genetically human, but  hold that they do not have the same moral relevance
because they lack specific capacities, including consciousness, reasoning and sentience.12
The NBAC received testimony from witnesses of many religious traditions that were open
to the use of early embryos (remaining from infertility treatments) for stem cell research
as well as many who were opposed.  “Jewish and Islamic ethicists supported stem cell
research while Protestant and Catholics were mixed. ...[W]hile the early human embryo
is worthy of respect, it ought not to be given personal moral status until there has been
sufficient development of the embryo.”13  Supporters argue that the potential human health
and scientific benefits the research holds should be an ethical argument for its support.
Patient groups have also asserted that, because of the potential of human stem cells for the
treatment of disease, it is immoral to discourage such research because it could save many
lives.  In addition, supporters believe that the oversight which would come with federal
grant support would result in better and more ethically controlled research in the field than
if funding was from private sources alone.  Supporters also argue that the efforts of both
federally supported and private researchers are necessary to keep the United States at the
forefront of what they believe is a very important, cutting edge area of science.
